CONGENITAL AND ACQUIRED INTERFERONOPATHIES: DIFFERENTIATED APPROACHES TO THE INTERFERON-CORRECTIVE THERAPY
https://doi.org/10.22627/2072-8107-2017-16-2-50-53
Abstract
Various disturbances in the interferon system (IFN) — interferonopathy are considered. The classification of developed by the author is given. The clinical features of Type I interferonopathy associated with the overexpression of type I interferons in the rare Mendelian genetic diseases, some autoimmune diseases, the immune dysregulation syndrome, are characterized. The developed methods of targeted therapy of type I interferonopathies aimed at blocking overexpression of type I interferons as hyperproduction IFNa are described. Interferonopathies most often occur as IFN deficiency: congenital or acquired IFNa/b and IFNg deficiencies in children and adults who are associated with atypical viral or mycobacterial infections. Patients with congenital IFNa deficiency are shown to have replacement interferon therapy. With the acquired deficiency of IFNa, differentiated interferon-corrective therapy is performed. For replacement and interferon-corrective therapy, it is used with good clinical efficacy, safe, no side effects, recombinant human IFNa2b in combination with antioxidants — VIFERONR.
About the Author
I. V. Nesterova
People’s Friendship University of Russia
Russian Federation
I.V. Nesterova, MD, Professor at the Department of Allergology and Immunology
Russian Federation
I.V. Nesterova, MD, Professor at the Department of Allergology and Immunology
References
1. Crow Y. Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci. 2011. Nov;1238:91—98.
2. Gunther C., Schmidt F., Konig N., Lee-Kirsch M. Type I interferonopathies. Systemic inflammatory diseases triggered by type I interferons. Z Rheumatol. 2016; 75(2):134—140.
3. Lee-Kirsch M. The Type I Interferonopathies. Annu Rev Med. 2017; 68(14):297—315.
4. Crow Y. Human type I interferonopathies. Cytokine. 2015; 76(1): 58.
5. Rodero M., Crow Y. Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview. J Exp Med. 2016; 213(12): 2527—2538.
6. Caielli S., Athale S., Domic B., et al. Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus. J Exp Med. 2016; 213(5): 697—713.
7. Khamashta M., Merrill J.,Werth V. et al. Sifalimumab, an anti-interferonmonoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016; 75(11):1909—1916.
8. Kalunian K., Merrill J., Maciuca R. et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016; 75(1):196—202.
9. Furie R., Khamashta M., Merrill J. et al. Anifrolumab, an Anti-InterferonReceptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017; 69(2): 376—386.
10. Нестерова И.В., Малиновская В.В., Тараканов В.А., Ковалева С.В. Интерфероно- и иммунотерапия в практике лечения часто и длительно болеющих детей и взрослых. Capricorn Publishing, Inc.USA, UK, Russia, 2004: 158. [Nesterova I.V., Malinovskaya V.V., Tarakanov V.A., Kovaleva S.V. Interferono- and immunotherapy in the practice of treating often and long-term ill children and adults. Capricorn Publishing, Inc.USA, UK, Russia, 2004: 158. (In Russ.)].
11. Al-Herz W., Bousfiha A., Casanova J.-L. et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Frontiers in Immunology. 2014; 5(6):1— 33.
12. Andersen L., Mork N., Reinert L., et al. Functional IRF3 deficiency in a patient with herpes simplex encephalitis. JEM. 2015; 212(9):1371—1379.
13. Нестерова И.В.,Сепиашвили Р.И. Иммунологические препараты и современная иммунотерапия в клинической иммунологии и медицине. Аллергология и иммунология. 2000; 3:18—28. [Nesterova I.V., Sepiashvili R.I. Immunological preparations and modern immunotherapy in clinical immunology and medicine. Allergology and Immunology. 2000; 3: 18—28. (In Russ.)].
14. Нестерова И.В. Иммуномодулирующая терапия направленного действия: сегодняшняя реальность и перспективы. Аллергология и иммунология. 2015;1:18—20. [Nesterova I.V. Immunomodulatory therapy directed action: today's reality and prospects. Allergology and Immunology. 2015; 1: 18—20. (In Russ.)].
15. Сепиашвили Р.И. Основные принципы применения иммуномодулирующих препаратов в клинической практике. Аллергология и иммунология. 2015;15(1): 70—74. [Sepiashvili R.I. Basic principles of the use of immunomodulating drugs in clinical practice. Allergology and Immunology. 2015; 15 (1): 70—74. (In Russ.)].
16. Nesterova I., Kovaleva S., Chudiliva G., Lomtatidze L. Defects in functioning of interferon and immune systems and their correction in chronic active Epstein-Barr infection. Allergy, Asthma & Immunophysiolosy: from basic science to clinical application. Medimond International Proceedings, 2012: 187—191.
17. Нестерова И.В., Ковалева С.В.,. Клещенко Е.И, Чудилова Г.А., Ломтатидзе Л.В., Шинкарева О.Н., Парфенов В.В., Кольцов В.Д. Оптимизация тактики интерфероно- и иммунотерапии в реабилитации иммунокомпрометированных детей с повторными респираторными и герпетическими вирусными инфекциями. Педиатрия. 2014; 93(3):66—72. [Nesterova I.V., Kovalev S.V., Kleshchenko E.I., Chudilova G.A., Lomtаtidze L.V., Shinkareva O.N., Parfenov V.V., Koltsov V.D. Optimization of the tactics of interferon and immunotherapy in the rehabilitation of immunocompromised children with repeated respiratory and herpetic viral infections. Pediatrics. 2014; 93 (3): 66—72. (In Russ.)].
18. Нестерова И.В. Интерфероны в практике клинициста: лучшие друзья или опасные враги. Аллергология и иммунология. 2016; 17(3):189—191. [Nesterova I.V. Interferons in the practice of a clinician: best friends or dangerous enemies. Allergology and Immunology. 2016; 17 (3): 189—191. (In Russ.)].
19. Нестерова И.В., Ковалева С.В., Чудилова Г.А., Ломтатидзе Л.В., Шинкарева О.Н., Малиновская В.В. Эффективность и безопасность ВИФЕРОНRа в моно- и комбинированной иммунотерапии иммунокомпрометированных детей с возвратными респираторными инфекциями. Фарматека. 2017; 4:48—56. [Nesterova I.V., Kovaleva S.V., Chudilova G.A., Lomtаtidze L.V., Shinkareva O.N., Malinovskaya V.V. Efficacy and safety of VIFERONR in mono- and combined immunotherapy of immunocompromised children with recurrent respiratory infections. Pharmatecа. 2017; 4: 48—56. (In Russ.)].
Review
For citations:
Nesterova I.V. CONGENITAL AND ACQUIRED INTERFERONOPATHIES: DIFFERENTIATED APPROACHES TO THE INTERFERON-CORRECTIVE THERAPY. CHILDREN INFECTIONS. 2017;16(2):50-53. (In Russ.) https://doi.org/10.22627/2072-8107-2017-16-2-50-53
Views:
2037
Email this article 